Manuscript no. HAEMATOL/2011/043331 entitled “Response of myeloma to proteasome inhibitor bortezomib is correlated with unfolded protein response regulator XBP-1“


Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
   • Silvia CW Ling, Centenary Institute of Cancer Medicine & Cell Biology, silviacwling@yahoo.com.au
   • John D Allen, Centenary Institute of Cancer Medicine & Cell Biology, john.allen@sydney.edu.au

According to the International Committee of Medical Journal Editors (ICMJE) ([http://www.icmje.org/ethical_1author.html](http://www.icmje.org/ethical_1author.html)): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …………………… Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Silvia Ling, P. Joy Ho, Douglas Joshua, John Allen

3) Design & Methods. The following authors were responsible for specific investigations (please detail):
   • Silvia Ling was responsible for most details of the study design and participated in all.
   • Ammira Al-Shabeeb was responsible for ELISA assay of secreted immunoglobulin.
   • Albert Catalano and Harry Iland assisted design of QPCR assays for XBP-1 and flow cytometric purification of myeloma cells.
   • Noemi Horvath was responsible for the BIR trial, the materials and the records provided.
   • Simon Harrison was responsible for materials, records and associated analysis from the Victorian Cancer Biobank.
   • Douglas Joshua was responsible for materials, records from the RPAH Institute of Haematology, as well as clinical and scientific oversight.
   • John Allen supervised the study and its design.

4) Results. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
   • Silvia Ling generated the results presented in all figures except 3A and 3E, where she supervised others (see below).
   • Edwin Lau assisted with flow cytometric purification of myeloma cells and XBP-1 assays: Figs 1 & 2.
   • Ammira Al-Shabeeb assisted with flow cytometric purification of myeloma cells (Fig 2) and was responsible for assay of Ig secretion (fig 3E).
   • Angela Nikolic was responsible for assaying proteasome activity (Fig 3A).
   • Shaun Fleming analysed Victorian Cancer Biobank patient records for results presented in Fig 2E.
• John Allen assisted with flow cytometric purification of myeloma cells, QPCR & cytotoxicity assays: Figs 1 & 2.

5) Writing the manuscript. The following authors were responsible for writing the manuscript:
• Silvia Ling and John Allen wrote the manuscript.
• All other authors contributed comments and corrections during the revision process.

6) Contributors Listed in Acknowledgments:
• Andrew Spencer, Daniel Sze, Denis Moss: provided cell lines